Uthappa Mukatira, PhD
Psychiatric/Mental Health · Cordova, TNNPI 1336519925
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 77.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $18,818 and has fallen 67.4% since, to $6,142 in 2025. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 553 payments — averaging $79.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$34K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$725
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$695
- Takeda Pharmaceuticals U.S.A., Inc.$678
- plus $4K from 21 others
What the payments were for
- Consulting fees$4,38010%
- Speaking & faculty fees$25,16357%
- Travel & lodging$3,3198%
- Food & beverage$10,99625%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 124 | $34,078 |
| Otsuka America Pharmaceutical, Inc. | 34 | $1,825 |
| AbbVie | 89 | $1,678 |
| Johnson & Johnson | 22 | $725 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $695 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $678 |
| Teva Pharmaceuticals USA, Inc. | 39 | $638 |
| Corium, LLC | 42 | $569 |
| Lundbeck LLC | 19 | $442 |
| Bausch Health US, LLC | 22 | $421 |
| Sunovion Pharmaceuticals Inc. | 17 | $317 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $295 |
| Supernus Pharmaceuticals, Inc. | 10 | $255 |
| Ironshore Pharmaceuticals Inc. | 14 | $240 |
| Neurocrine Biosciences, Inc. | 11 | $190 |
| Vanda Pharmaceuticals Inc. | 2 | $152 |
| Axsome Therapeutics, Inc. | 6 | $131 |
| Jazz Pharmaceuticals Inc. | 1 | $123 |
| Tris Pharma Inc | 7 | $116 |
| Adlon Therapeutics L.p. | 4 | $86 |
| Myriad Genetic Laboratories, Inc. | 1 | $66 |
| Biogen | 2 | $65 |
| Merck | 5 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Indivior Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,961 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,249 |
| Aripiprazole | 31 | $2,128 |
| Bupropion XlBupropion Hcl | 55 | $2,039 |
| Divalproex Sodium | 14 | $1,471 |
| Quetiapine Fumarate | 56 | $1,402 |
| Duloxetine Hcl | 31 | $1,194 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $771 |
| Trazodone Hcl | 46 | $747 |
| Buspirone Hcl | 23 | $711 |
| Lamotrigine | 45 | $569 |
| Alprazolam | 65 | $511 |
| Bupropion Hcl SrBupropion Hcl | 13 | $486 |
| Propranolol Hcl | 17 | $430 |
| Fluoxetine Hcl | 15 | $422 |
| Escitalopram Oxalate | 18 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $678 | $9,24923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Cordova
- Derrick MeadowCordova$34K
- John RedmondCordova$23K
- Mark HesselrodeCordova$9K
- Amanda WoodallCordova$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.